Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.78 |
| ▸ | POLA1 | P09884 | 1/20 | 0.74 |
| ▸ | POLD1 | P28340 | 1/20 | 0.74 |
| ▸ | DTYMK | P23919 | 4/20 | 0.65 |
| ▸ | TYMS | P04818 | 1/20 | 0.65 |
| ▸ | TK1 | P04183 | 3/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Deoxythymidine_Triphosphate SCHEMBL77832 | 1.00 | POLB (0.78) | POLBPOLA1POLD1DTYMKTYMS | |
| Telbivudine 5'Triphosphate SCHEMBL29725270 | 1.00 | POLB (0.78) | POLBPOLA1POLD1DTYMKTYMS | |
| Deoxythymidine_Triphosphate SCHEMBL77831 | 1.00 | POLB (0.78) | POLBPOLA1POLD1DTYMKTYMS | |
| Deoxythymidine_Triphosphate SCHEMBL14279191 | 1.00 | POLB (0.78) | POLBPOLA1POLD1DTYMKTYMS | |
| Deoxythymidine_Triphosphate SCHEMBL1579556 | 1.00 | POLB (0.78) | POLBPOLA1POLD1DTYMKTYMS | |
| Deoxythymidine_Triphosphate SCHEMBL11055949 | 1.00 | POLB (0.78) | POLBPOLA1POLD1DTYMKTYMS | |
| Deoxythymidine_Triphosphate SCHEMBL18785124 | 1.00 | POLB (0.78) | POLBPOLA1POLD1DTYMKTYMS | |
| Deoxythymidine_Triphosphate SCHEMBL21275938 | 1.00 | POLB (0.78) | POLBPOLA1POLD1DTYMKTYMS | |
| SCHEMBL21682516 | 1.00 | POLB (0.78) | POLBPOLA1POLD1DTYMKTYMS | |
| SCHEMBL4370525 | 1.00 | POLB (0.78) | POLBPOLA1POLD1DTYMKTYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1005327-A1 | TARGETED LIPOSOMAL CONSTRUCTS FOR DIAGNOSTIC AND THERAPEUTIC USES | SDG, INC. (US) | 2000-06-07 | — | — | EP | claimed |
| US-6063400-A | CARRIER; DIAGNOSTIC OR THERAPEUTIC AGENT AND SEQUESTERING AGENT | SDG, INC. (US) | 2000-05-16 | — | — | US | claimed |
| WO-1999001110-A1 | TARGETED LIPOSOMAL CONSTRUCTS FOR DIAGNOSTIC AND THERAPEUTIC USES | SDG, INC. (US) | 1999-01-14 | — | — | WO | claimed |
| US-8058031-B2 | Labeled nucleotide analogs and uses therefor | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) | 2011-11-15 | — | — | US | disclosed |
| US-20110059450-A1 | LABELED NUCLEOTIDE ANALOGS AND USES THEREFOR | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) | 2011-03-10 | — | — | US | disclosed |
| US-7777013-B2 | Labeled nucleotide analogs and uses therefor | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-20090018324-A1 | LABELED NUCLEOTIDE ANALOGS AND USES THEREFOR | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) | 2009-01-15 | — | — | US | disclosed |
| US-7405281-B2 | Fluorescent nucleotide analogs and uses therefor | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| EP-1937702-A2 | LABELED NUCLEOTIDE ANALOGS AND USES THEREFOR | Pacific Biosciences of California, Inc. (US) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007041342-A2 | LABELED NUCLEOTIDE ANALOGS AND USES THEREFOR | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) | 2007-04-12 | — | — | WO | disclosed |
| US-20070072196-A1 | Fluorescent nucleotide analogs and uses therefor | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) | 2007-03-29 | — | — | US | disclosed |
| EP-1005327-A1 | TARGETED LIPOSOMAL CONSTRUCTS FOR DIAGNOSTIC AND THERAPEUTIC USES | SDG, INC. (US) | 2000-06-07 | — | — | EP | disclosed |
| US-6063400-A | CARRIER; DIAGNOSTIC OR THERAPEUTIC AGENT AND SEQUESTERING AGENT | SDG, INC. (US) | 2000-05-16 | — | — | US | disclosed |
| WO-1999001110-A1 | TARGETED LIPOSOMAL CONSTRUCTS FOR DIAGNOSTIC AND THERAPEUTIC USES | SDG, INC. (US) | 1999-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072196-A1 | Fluorescent nucleotide analogs and uses therefor | DNTT, POLRMT, RNGTT | POLB 18/4885POLA1 152/4885POLD1 483/4885 |
| US-20090018324-A1 | LABELED NUCLEOTIDE ANALOGS AND USES THEREFOR | POLRMT, DNTT, NUDT1 | POLB 14/4885POLA1 128/4885POLD1 341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.